- Published on
KembaraXtra-Medicine – Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental condition characterized by persistent patterns of inattention and/or hyperactivity–impulsivity. Symptoms begin in childhood, persist for at least six months, and cause functional impairment across multiple settings such as home, school, or social environments. ADHD is also referred to as attention deficit disorder (ADD), hyperactivity, or attention deficit syndrome with hyperactivity. Diagnostic classifications include ICD-11 codes (6A05 series) and DSM-5 presentations that are predominantly inattentive, predominantly hyperactive-impulsive, or combined.
ADHD is the most common neurodevelopmental disorder in children, affecting approximately 9%–15% of school-age children, up to 14% of adolescents, and 3%–5% of adults. It is diagnosed more often in males during childhood, particularly in the hyperactive type, while adult prevalence is closer to equal between sexes. Symptoms must be present before age 12, commonly leading to diagnosis between ages 6 and 9. Although hyperactivity may decrease with age, many individuals continue to experience symptoms into adolescence and adulthood.
Risk factors include genetic predisposition, prenatal exposure to tobacco, alcohol, or illicit substances, prematurity, low birth weight, lead exposure, head trauma in early childhood, and psychosocial stressors such as family dysfunction or low socioeconomic status. Genetics play a major role, with first-degree relatives having a two- to sixfold increased risk. Neuroimaging studies show structural and functional brain differences, particularly in frontal and prefrontal regions, although these findings are not diagnostic.
Clinically, ADHD presents in three patterns. The predominantly inattentive type involves difficulty organizing, sustaining attention, remembering tasks, and completing work. The predominantly hyperactive-impulsive type features restlessness, excessive talking, impulsivity, and difficulty waiting or inhibiting responses. The combined type includes features of both. ADHD commonly coexists with other conditions such as learning disabilities, oppositional defiant disorder, autism spectrum disorder, anxiety, depression, and substance use disorders. In adults, overt hyperactivity is less common, while restlessness, disorganization, and difficulty completing tasks predominate.
The etiology of ADHD is multifactorial, with strong genetic influences and contributions from altered catecholamine metabolism, delayed cortical maturation, disrupted reward processing, and environmental factors. Dopamine and norepinephrine pathways in the prefrontal cortex are central to attention, executive function, and impulse control and are key to ADHD pathophysiology.
Diagnosis is clinical and based on a thorough history and assessment of symptoms across settings. Differential diagnoses include medical conditions (e.g., hearing or vision impairment, thyroid disease, seizures), psychiatric disorders (e.g., mood disorders, anxiety, autism spectrum disorder), and psychosocial factors. Evaluation should include collateral information from parents, teachers, or partners, as well as the use of ADHD-specific rating scales. Laboratory tests and imaging are not routinely required unless indicated by history or examination.
Treatment is individualized and often multimodal. Pharmacologic therapy, particularly stimulant medications, is the mainstay and has the strongest evidence for symptom control. Stimulants act by increasing dopamine and norepinephrine availability and are available in multiple short- and long-acting formulations. Atomoxetine is a nonstimulant alternative, typically used when stimulants are ineffective or contraindicated. Other options include antidepressants and alpha-2 adrenergic agonists such as clonidine and guanfacine. Medications require regular monitoring for side effects, including cardiovascular effects, appetite suppression, sleep disturbance, and mood changes.
Nonpharmacologic interventions include behavioral therapy, parent training, educational accommodations, organizational skills training, and social skills interventions. These approaches are particularly important for younger children, mild cases, or when comorbid conditions are present. Educational support through individualized plans or 504 accommodations is recommended. Digital therapeutics and structured behavioral strategies may provide additional benefit, while elimination diets and psychotherapy alone are generally not effective for core ADHD symptoms.
ADHD is often a lifelong condition with symptoms persisting into adulthood in a substantial proportion of patients. Long-term risks include academic and occupational difficulties, psychiatric comorbidities, substance use disorders, and impaired social functioning. Referral to a specialist is recommended when diagnosis is uncertain, comorbidities are complex, or response to first-line treatments is inadequate. Early recognition and appropriate treatment improve functional outcomes and quality of life.
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental condition characterized by persistent patterns of inattention and/or hyperactivity–impulsivity. Symptoms begin in childhood, persist for at least six months, and cause functional impairment across multiple settings such as home, school, or social environments. ADHD is also referred to as attention deficit disorder (ADD), hyperactivity, or attention deficit syndrome with hyperactivity. Diagnostic classifications include ICD-11 codes (6A05 series) and DSM-5 presentations that are predominantly inattentive, predominantly hyperactive-impulsive, or combined.
ADHD is the most common neurodevelopmental disorder in children, affecting approximately 9%–15% of school-age children, up to 14% of adolescents, and 3%–5% of adults. It is diagnosed more often in males during childhood, particularly in the hyperactive type, while adult prevalence is closer to equal between sexes. Symptoms must be present before age 12, commonly leading to diagnosis between ages 6 and 9. Although hyperactivity may decrease with age, many individuals continue to experience symptoms into adolescence and adulthood.
Risk factors include genetic predisposition, prenatal exposure to tobacco, alcohol, or illicit substances, prematurity, low birth weight, lead exposure, head trauma in early childhood, and psychosocial stressors such as family dysfunction or low socioeconomic status. Genetics play a major role, with first-degree relatives having a two- to sixfold increased risk. Neuroimaging studies show structural and functional brain differences, particularly in frontal and prefrontal regions, although these findings are not diagnostic.
Clinically, ADHD presents in three patterns. The predominantly inattentive type involves difficulty organizing, sustaining attention, remembering tasks, and completing work. The predominantly hyperactive-impulsive type features restlessness, excessive talking, impulsivity, and difficulty waiting or inhibiting responses. The combined type includes features of both. ADHD commonly coexists with other conditions such as learning disabilities, oppositional defiant disorder, autism spectrum disorder, anxiety, depression, and substance use disorders. In adults, overt hyperactivity is less common, while restlessness, disorganization, and difficulty completing tasks predominate.
The etiology of ADHD is multifactorial, with strong genetic influences and contributions from altered catecholamine metabolism, delayed cortical maturation, disrupted reward processing, and environmental factors. Dopamine and norepinephrine pathways in the prefrontal cortex are central to attention, executive function, and impulse control and are key to ADHD pathophysiology.
Diagnosis is clinical and based on a thorough history and assessment of symptoms across settings. Differential diagnoses include medical conditions (e.g., hearing or vision impairment, thyroid disease, seizures), psychiatric disorders (e.g., mood disorders, anxiety, autism spectrum disorder), and psychosocial factors. Evaluation should include collateral information from parents, teachers, or partners, as well as the use of ADHD-specific rating scales. Laboratory tests and imaging are not routinely required unless indicated by history or examination.
Treatment is individualized and often multimodal. Pharmacologic therapy, particularly stimulant medications, is the mainstay and has the strongest evidence for symptom control. Stimulants act by increasing dopamine and norepinephrine availability and are available in multiple short- and long-acting formulations. Atomoxetine is a nonstimulant alternative, typically used when stimulants are ineffective or contraindicated. Other options include antidepressants and alpha-2 adrenergic agonists such as clonidine and guanfacine. Medications require regular monitoring for side effects, including cardiovascular effects, appetite suppression, sleep disturbance, and mood changes.
Nonpharmacologic interventions include behavioral therapy, parent training, educational accommodations, organizational skills training, and social skills interventions. These approaches are particularly important for younger children, mild cases, or when comorbid conditions are present. Educational support through individualized plans or 504 accommodations is recommended. Digital therapeutics and structured behavioral strategies may provide additional benefit, while elimination diets and psychotherapy alone are generally not effective for core ADHD symptoms.
ADHD is often a lifelong condition with symptoms persisting into adulthood in a substantial proportion of patients. Long-term risks include academic and occupational difficulties, psychiatric comorbidities, substance use disorders, and impaired social functioning. Referral to a specialist is recommended when diagnosis is uncertain, comorbidities are complex, or response to first-line treatments is inadequate. Early recognition and appropriate treatment improve functional outcomes and quality of life.
0 Comments
